Trulicity, also known as dulaglutide, received its initial U.S. Food and Drug Administration (FDA) approval on November 3, 2014 [1]. It is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes [2].
When does Trulicity patent protection end?
Patent protection for Trulicity is complex, involving multiple patents covering its composition, methods of use, and manufacturing [3]. DrugPatentWatch.com tracks these patents, noting that some key patents may expire around 2027, while others extend further [3]. The exact timeline for when generic versions could become available depends on the expiration of these various patents and any potential patent challenges or extensions [3].
How does Trulicity work?
Trulicity functions by mimicking the action of the incretin hormone GLP-1. It stimulates insulin secretion from the pancreas in a glucose-dependent manner, meaning it only releases insulin when blood glucose levels are high. It also suppresses glucagon secretion, which helps lower glucose production by the liver, and slows gastric emptying, contributing to a feeling of fullness [2].
What are the alternatives to Trulicity?
Other medications for type 2 diabetes include other GLP-1 receptor agonists, such as liraglutide (Victoza, Saxenda), semaglutide (Ozempic, Rybelsus, Wegovy), and exenatide (Byetta, Bydureon) [4]. Other classes of diabetes medications include metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and insulin [5]. The choice of treatment depends on individual patient needs, comorbidities, and treatment goals [5].
Who manufactures Trulicity?
Trulicity is manufactured by Eli Lilly and Company [1].